Alpha-lipoic acid for diabetic neuropathy: what does the evidence show?

1. What is alpha-lipoic acid?

Alpha-lipoic acid is a compound the body makes in small amounts, and it is also sold as a dietary supplement. It plays a role in energy metabolism and works as an antioxidant, which means it can help neutralize unstable molecules that may irritate or damage tissues.

Neuropathy simply means nerve damage. In diabetic peripheral neuropathy, nerves — especially those in the feet and lower legs — can be injured by long-term high blood glucose, blood vessel changes, inflammation, and oxidative stress. Common neuropathy symptoms include pain, burning, pins and needles, numbness, and reduced sensation.

ALA has drawn interest because oxidative stress is one part of the diabetic neuropathy picture. But the key question is not just whether ALA behaves like an antioxidant in the lab. It is whether people actually feel better, or show better nerve function, in clinical trials.

2. How ALA might help nerves

The proposed idea is fairly straightforward. In diabetes, nerves can be exposed to metabolic stress, poorer blood flow, and oxidative damage. ALA may reduce some of that oxidative stress and may support nerve blood flow in ways that could quiet irritated nerves.

That fits what many trials have seen: symptoms such as burning and pain can improve over a few weeks. But feeling better is not the same as repairing the nerve. To show true disease modification, studies need to show lasting improvement in more objective outcomes, such as nerve conduction, vibration perception, neurological impairment scores, ulceration, amputation, or quality of life. That evidence has been much harder to pin down.

3. What short-term trials found

The strongest early results came from intravenous ALA. In the ALADIN trial, 328 adults with symptomatic diabetic peripheral neuropathy received IV ALA at 100, 600, or 1200 mg per day, or placebo, for 3 weeks. The 600 mg group had a large reduction in Total Symptom Score, a scale that captures symptoms such as pain, burning, tingling, and numbness. More people also achieved at least a 30% symptom improvement compared with placebo.

A later pooled analysis of four double-blind trials, including 1258 participants, found that IV ALA 600 mg per day for 3 weeks improved Total Symptom Score and a lower-limb neurological impairment score more than placebo. Pain, burning, and numbness all improved. At this dose, adverse-event rates were similar to placebo.

The SYDNEY trial, another 3-week IV study, also reported improvement in positive sensory symptoms. Put together, the short-course IV evidence is the clearest part of the ALA story: it appears useful for easing symptoms over a few weeks in diabetic peripheral neuropathy.

4. Oral ALA: promising, but less consistent

Oral ALA is easier to use than IV treatment, but the evidence is less tidy. One reason is absorption. Oral ALA has limited bioavailability, meaning some of it is broken down before it reaches the bloodstream.

The SYDNEY 2 trial tested oral ALA at 600, 1200, and 1800 mg per day for 5 weeks. All active doses improved sensory symptom scores compared with placebo, but higher doses caused more side effects, especially digestive symptoms. This is one reason 600 mg per day has become the commonly studied oral dose: it seemed to fall near the useful part of the dose-response curve, without the tolerability problems seen more often at 1200 to 1800 mg.

A 2023 meta-analysis of 10 oral ALA trials found favorable effects on Total Symptom Score, Neuropathy Disability Score, and global satisfaction. However, it did not find clear pooled benefits for visual analogue pain scores, vibration perception threshold, lower-limb impairment, or nerve conduction outcomes. In plain English: oral ALA may improve symptom scores, but the case for measurable nerve repair is weaker.

A 2022 review of the broader trial literature also found inconsistent results: three studies reported significant symptom improvement, while five did not find a notable benefit. That does not cancel out the positive trials, but it does mean oral ALA should not be oversold as a reliable treatment for everyone.

5. Does ALA slow neuropathy progression?

This is the harder question. Long-term trials tell us more about progression than 3-week symptom studies.

ALADIN III tested IV ALA for 3 weeks followed by high-dose oral ALA for 6 months. The results were mixed. Some neurological signs improved early, but symptom differences from placebo were weaker than expected, and the longer-term advantage was borderline or not clearly significant.

ALADIN II, a 2-year study, has been summarized as showing improvement in nerve conduction studies with oral ALA at 600 or 1200 mg per day. That sounds encouraging, but the accessible reporting is thinner than it is for later studies, so it is harder to weigh with confidence.

The pivotal long-term trial is NATHAN 1. In this 4-year study, 460 people with mild-to-moderate diabetic polyneuropathy took oral ALA 600 mg per day or placebo. ALA did not improve the primary composite endpoint, which included lower-limb impairment plus several nerve tests. It did improve some secondary neurological impairment measures, especially small-fiber and muscle-related signs, but nerve conduction did not clearly improve.

A 2024 Cochrane review focused on placebo-controlled trials lasting 6 months to 4 years. It concluded that ALA probably has little or no effect on neuropathy symptoms at 6 months and may have little or no effect on impairment. It found no clear evidence for quality-of-life benefit, ulceration, or amputation outcomes. This review is especially useful because it looks beyond very short symptom trials and asks whether longer treatment changes the disease picture.

The fairest reading is this: ALA looks more convincing as a symptom-relief option than as a proven disease-modifying therapy.

6. Safety and practical considerations

At studied doses, ALA is generally well tolerated. Common side effects include headache, heartburn, nausea, vomiting, abdominal discomfort, constipation or diarrhea, dizziness, and other digestive upset. These are more likely at higher oral doses such as 1200 to 1800 mg per day.

ALA is not approved by the U.S. Food and Drug Administration to treat neuropathy or any medical condition. The American Diabetes Association notes that ALA is not approved for painful diabetic peripheral neuropathy, but it may be effective and can be considered.

Large overdoses are a different situation. Safety references describe severe toxicity after very high intakes, including seizures, lactic acidosis, rhabdomyolysis, coma, and multiorgan failure. That is not the usual experience at studied doses, but it is a good reason not to exceed label directions or casually combine multiple products.

Evidence outside diabetic neuropathy is much thinner. For example, an oral ALA trial in platinum chemotherapy-induced peripheral neuropathy had high dropout and poor compliance, and did not establish a practical benefit. Results from diabetic neuropathy should not be assumed to apply to every cause of nerve pain.